Liver Fibrosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Inventiva Pharma, Galmed Research and Development, Ltd.

Posted on
by

Liver Fibrosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Inventiva Pharma, Galmed Research and Development, Ltd.
DelveInsight’s “Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Liver Fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.  

 

Liver Fibrosis Overview

Liver fibrosis is caused by the accumulation of extracellular matrix (ECM) proteins, mostly collagens Type I and Type III, followed by the formation of fibrous scar, which can ultimately compromise normal liver function. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.

Liver fibrosis diagnosis cannot be made in its mild to moderate stages, and this is because liver fibrosis does not usually cause symptoms until more of the liver is damaged. While progressing towards liver disease, the patient may experience symptoms including appetite loss, fluid buildup in the legs or stomach, jaundice, nausea, unexplained weight loss, and many others

Some of the key facts of the Liver Fibrosis Market Report: 

  • The Liver Fibrosis market size was estimated at USD 2,225 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • In 2021, nearly 19,126,579 Diagnosed Prevalent Cases of Liver Fibrosis occurred in the 7MM 
  • The United States presented the highest Diagnosed Prevalent Cases of Liver Fibrosis in2021around 9,488,135 cases 
  • Among the European countries, Germany had the highest Diagnosed Prevalent Cases of Liver Fibrosis with 1,641,162 cases, followed by Italy with 1,532,651 cases in 2021 
  • Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., ZydusTherapeutics, Axcella, Rivus Pharmaceuticals, Inc., Lipocine Inc., Novo Nordisk, HighTide Biopharma, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc, and others 
  • Key Liver Fibrosis Therapies: Lanifibranor, Aramchol, MGL-3196, Obeticholic acid, Pegozafermin, Saroglitazar Magnesium, AXA1125, HU6, LPCN 1144, Semaglutide, HTD1801 , Efruxifermin, Vonafexor, TVB-2640, and others 

 

Get a Free sample for the Liver Fibrosis Market Report 

 

Key benefits of the Liver Fibrosis Market report:

  1. Liver Fibrosis market report covers a descriptive overview and comprehensive insight of the Liver Fibrosis Epidemiology and Liver Fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Liver Fibrosis market report provides insights on the current and emerging therapies.
  3. Liver Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Liver Fibrosis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Liver Fibrosis market.

 

Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis market forecast 

 

Liver Fibrosis Epidemiology Segmentation:

The Liver Fibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Liver Fibrosis
  • Prevalent Cases of Liver Fibrosis by severity
  • Gender-specific Prevalence of Liver Fibrosis
  • Diagnosed Cases of Episodic and Chronic Liver Fibrosis 

 

Liver Fibrosis Market  

The dynamics of the Liver Fibrosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Aramchol, MGL-3196, and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiological Insights 

 

Liver Fibrosis Market Drivers

  • Rich emerging pipeline
  • Understanding of pathophysiology
  • Increased awareness

Liver Fibrosis Therapies and Key Companies 

  • Lanifibranor: Inventiva Pharma
  • Aramchol: Galmed Research and Development, Ltd
  • MGL-3196: Madrigal Pharmaceuticals, Inc.
  • Obeticholic acid: Intercept Pharmaceuticals
  • Pegozafermin: 89bio Inc.
  • Saroglitazar Magnesium: ZydusTherapeutics
  • AXA1125: Axcella
  • HU6: Rivus Pharmaceuticals, Inc.
  • LPCN 1144: Lipocine Inc.
  • Semaglutide: Novo Nordisk
  • HTD1801: HighTide Biopharma
  • Efruxifermin: Akero Therapeutics, Inc
  • Vonafexor: Enyo Pharma
  • TVB-2640: Sagimet Biosciences Inc 

 

Scope of the Liver Fibrosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., ZydusTherapeutics, Axcella, Rivus Pharmaceuticals, Inc., Lipocine Inc., Novo Nordisk, HighTide Biopharma, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc, and others
  • Key Liver Fibrosis Therapies: Lanifibranor, Aramchol, MGL-3196, Obeticholic acid, Pegozafermin, Saroglitazar Magnesium, AXA1125, HU6, LPCN 1144, Semaglutide, HTD1801 , Efruxifermin, Vonafexor, TVB-2640, and others
  • Liver Fibrosis Therapeutic Assessment:  Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
  • Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Liver Fibrosis  Market Access and Reimbursement 

 

Liver Fibrosis Market Barriers

  • No standard treatment
  • Insufficient delivery of anti-fibrotic drugs
  • High economic burden
  • Complex mechanisms

 

Table of Contents 

1. Liver Fibrosis Market Report Introduction

2. Executive Summary for Liver Fibrosis

3. SWOT analysis of Liver Fibrosis

4. Liver Fibrosis Patient Share (%) Overview at a Glance

5. Liver Fibrosis Market Overview at a Glance

6. Liver Fibrosis Disease Background and Overview

7. Liver Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Fibrosis 

9. Liver Fibrosis Current Treatment and Medical Practices

10. Liver Fibrosis Unmet Needs

11. Liver Fibrosis Emerging Therapies

12. Liver Fibrosis Market Outlook

13. Country-Wise Liver Fibrosis Market Analysis (2019–2032)

14. Liver Fibrosis Market Access and Reimbursement of Therapies

15. Liver Fibrosis Market drivers

16. Liver Fibrosis Market barriers

17.  Liver Fibrosis Appendix

18. Liver Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Liver Fibrosis treatment, visit @ Liver Fibrosis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/